Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1776-260X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer ; day:10 ; month:11 ; year:2021 ; pages:1
Targeted oncology ; (10.11.2021), 1
- Urheber
-
Lee, Arnold
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-021-00854-x
- URN
-
urn:nbn:de:101:1-2022012208342417015726
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lee, Arnold
- SpringerLink (Online service)
Ähnliche Objekte (12)
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
AIH Therapy: Beyond First-Line
Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
AIH Therapy: Beyond First-Line
Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
Advanced Adrenocortical Carcinoma – What to do when First-Line Therapy Fails?
Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
AIH Therapy: Beyond First-Line
Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis